CD274 and triple-negative breast carcinoma: Several authors have shown that a significant percentage of Triple Negative breast cancer (TNBC) patients can benefit from the use of immune checkpoint inhibitors (ICBs), especially in cases of programmed cell death-ligand 1 (PD-L1) expression [4].